Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the TDI01 “ROCK2 inhibitor” independently developed by the group for the treatment of idiopathic pulmonary fibrosis (IPF) has completed the first patient enrollment. It is the first ROCK2 highly selective inhibitor in the world to enter IPF phase III clinical trials.

Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the TDI01 “ROCK2 inhibitor” independently developed by the group for the treatment of idiopathic pulmonary fibrosis (IPF) has completed the first patient enrollment. It is the first ROCK2 highly selective inhibitor in the world to enter IPF phase III clinical trials.